National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov

NCI Home
Cancer Topics
Clinical Trials
Cancer Statistics
Research & Funding
News
About NCI
NCI Drug Dictionary
Page Options
Print This Page
More NCI Dictionaries
Dictionary of Cancer Terms

Glossary of Statistical Terms

NCI Dictionary of Genetics Terms

Terminology Resources
Quit Smoking Today
Search for
# A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All

esorubicin
A synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)

Synonyms:deoxyadriamycin
deoxyadriamycin hydrochloride
deoxydoxorubicin
Code name:IMI-58
Chemical structure names:
  • 4'-deoxyadriamycin hydrochloride
  • 4'deoxydoxorubicin



Previous:erythromycin, erythromycin topical cream, escitalopram oxalate, Eskalith, esomeprazole magnesium
Next:Essiac, Estinyl, Estrace, estradiol vaginal ring, estradiol valerate

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov